Navigation Links
PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
Date:9/26/2008

e Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Form 10-K under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, just because the DHHS has awarded this contract to the Company for the advanced development of our third generation rPA anthrax vaccine, there can be no assurance that (1) the work under this contract will result in a safe and effective anthrax vaccine approved for use in humans, (2) DHHS will exercise all options under the contract, or (3) DHHS or any other government agencies or departments will ever procure doses of our third generation rPA vaccine for civilian or military purposes. Copies of PharmAthene's public disclosure filings are available from its investor relations department and o
'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
2. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
3. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
4. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
5. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
6. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
7. PharmAthene Reports First Quarter 2008 Financial Results
8. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
9. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
10. PharmAthene Reports Year-End 2007 Financial Results
11. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... LOS ANGELES , May 5, 2015 ... and pioneer in providing on-demand access to scientific, technical ... purchasing agreement with the Association of Southeastern Research ... of 38 research libraries located across 11 southeastern states. ... developing innovative and collaborative programs to address the continually ...
(Date:5/5/2015)... , May 05, 2015 Research and ... the addition of the "Clinical Laboratory, Molecular ... Forecast 2015 to 2019 - Global Version" ... developments especially in the area of molecular diagnostics ... growing and evolving world market that is moving ...
(Date:5/5/2015)... Hills, MI (PRWEB) May 05, 2015 ... premier Parker Hannifin distributor, announces the launch of ... provide fleet operators with a convenient way to ... maintenance products . , The new ... to 100,000 vehicles with direct access to high ...
(Date:5/4/2015)... 2015 Many of us take a ... infants with rare, inherited mutations of certain genes, ... their impaired immune responses. Now, researchers ... important role for calcium signaling in immune responses ... bacterium causing tuberculosis (TB). Specifically, ...
Breaking Biology Technology:Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Exotic Automation & Supply Launches Ecommerce Website 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3
... SEATTLE, March 6 Dendreon Corporation,(Nasdaq: DNDN ) will release ... will host a conference call at,8:00 a.m. PT; 11:00 a.m. ET ... Access to the discussion may be,obtained as follows:, ... Date: March 13, 2008 ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or ... year ended December 31, 2007., "2007 was ... significant,expansion of the Company,s clinical trial program for ... studies being expanded and,initiated," said Dr. Brad Thompson, ...
... announces that it has,purchased 75% of Hisyn ... already issued the necessary business license and ... The acquisition provides Hovione with significant additional ... 20 year,presence in China. The acquisition includes ...
Cached Biology Technology:-Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET- 2Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 2Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 3Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 4Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 5Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 6Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 7Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 8Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 9Hovione Buys Drug Manufacturing Facility in China 2
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... nerve cell degeneration plays a crucial role. In the future, ... generation and/or migration mechanism. These findings have been published in ... . Until only a few years ago, neurogenesis the ... impossible in the adult brain. The textbooks asserted that dead ...
... Yehezkel Ben-Ari, winner of the 2009 Inserm Grand Prix. ... to paying tribute to outstanding,work performed in its laboratories ... diversity and wealth of activities involved in today,s biological, ... the men and women who carry out and,drive this ...
... world first, a Monash University-led international research team has ... the next generation of solar cells. Scientists at ... of Wollongong and Ulm in Germany, have produced tandem ... conversion efficiency compared with previously reported tandem dye-sensitised solar ...
Cached Biology News:New source discovered for the generation of nerve cells in the brain 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3Innovation puts next-generation solar cells on the horizon 2
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... ECL Plus Western Blotting Reagent Pack, 1. ... secondary detection of membrane-bound mouse and rabbit ... or PVDF membranes. Detection reagents are not ... use with ECL Plus. Category: Blotting ...
... the LVF-UV-HL, LVF-CUV-ADP, FHS-LVF and CVD-Diffuse ... Linear Variable Filters to create the world's ... wavelength and adjustable bandpass. Each filter features ... band (99.8%). These filters -- with ...
Request Info...
Biology Products: